Effect of memantine on CBF and CMRO2 in patients with early Parkinson's disease

Acta Neurologica Scandinavica

Volumn 117, Issue 5, 2008, Pages 317-323

  Borghammer, P ^a   Vafaee, M ^a   Ostergaard, K ^a   Rodell, A ^a   Bailey, C ^b   Cumming, P ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Cerebral blood flow; CMRO2; Memantine; NMDA; Oxygen metabolism; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXYGEN 15; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN OXYGEN CONSUMPTION; BRAIN REGION; CLINICAL ARTICLE; DRUG DOSE ESCALATION; ENERGY METABOLISM; FEMALE; FRONTAL CORTEX; HEMISPHERE; HUMAN; MALE; METABOLIC RATE; NEUROMODULATION; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS;

AGED; ANTIPARKINSON AGENTS; BRAIN; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMANTINE; MIDDLE AGED; OXYGEN; OXYGEN RADIOISOTOPES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 41849139267     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00943.x     Document Type: Article

References (33)

1. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998 44 : S110 4.
2. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999 38 : 735 67.
3. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006 5 : 160 70.
4. Uitti RJ, Rajput AH, Ahlskog JE et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996 46 : 1551 6.
5. Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993 613 : 143 8.
6. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995 293 : 267 70.
7. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996 71 : 1043 8.
8. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev 1997 21 : 455 68.
9. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990 53 : 245 9.
10. Vafaee MS, Gjedde A. Spatially dissociated flow-metabolism coupling in brain activation. Neuroimage 2004 21 : 507 15.
11. Brabner G, Janke AL, Budge MM, Smith D, Pruessner J, Collins DL. Symmetric atlasing and model based segmentation: an application to the hippocampus in older adults. In : Larsen R, Nielsen M, Sporring J, eds. Medical image computing and computer-assisted intervention - MICCAI 2006. Berlin : Springer-Verlag, 2006 58 66.
12. 15O]water clearance in humans determined by PET: I. Theory and normal values. J Cereb Blood Flow Metab 1996 16 : 765 80.
13. Ohta S, Meyer E, Thompson CJ, Gjedde A. Oxygen consumption of the living human brain measured after a single inhalation of positron emitting oxygen. J Cereb Blood Flow Metab 1992 12 : 179 92.
14. Zijdenbos AP, Forghani R, Evans AC. Automatic 'pipeline' analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 2002 21 : 1280 91.
15. Worsley KJ, Liao CH, Aston J et al. A general statistical analysis for fMRI data. Neuroimage 2002 15 : 1 15.
16. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp 1996 4 : 58 73.
17. Pelligrino DA, Gay RL 3rd., Baughman VL, Wang Q. NO synthase inhibition modulates NMDA-induced changes in cerebral blood flow and EEG activity. Am J Physiol 1996 271 : H990 5.
18. Bari F, Nagy K, Guidetti P, Schwarcz R, Busija DW, Domoki F. Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs. Brain Res 2006 1069 : 39 46.
19. Faraci FM, Breese KR. Nitric oxide mediates vasodilatation in response to activation of N-methyl-d-aspartate receptors in brain. Circ Res 1993 72 : 476 80.
20. Bhardwaj A, Northington FJ, Carhuapoma JR et al. P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-d- aspartate. Am J Physiol Heart Circ Physiol 2000 279 : H1616 24.
21. Beart PM, Sheehan KA, Manallack DT. Absence of N-methyl-d-aspartate receptors on ovine cerebral microvessels. J Cereb Blood Flow Metab 1988 8 : 879 82.
22. Verkhratsky A, Kirchhoff F. NMDA receptors in glia. Neuroscientist 2007 13 : 28 37.
23. Vila M, Marin C, Ruberg M et al. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J Neurochem 1999 73 : 344 52.
24. Orieux G, Francois C, Feger J, Hirsch EC. Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J Neurosci 2002 22 : 8762 70.
25. Alexander GE, Crutcher MD, Delong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res 1990 85 : 119 46.
26. Middleton FA, Strick PL. Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb Cortex 2002 12 : 926 35.
27. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999 22 : 273 6.
28. Mcshane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006 CD003154.
29. 3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int 1998 33 : 29 34.
30. 3H]dopamine turnover in striatum and frontal cortex in vivo linked to glutamate receptor antagonism. J Neurochem 1998 70 : 1979 85.
31. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999 34 : 313 8.
32. 11)C]raclopride study. J Neural Transm 2002 109 : 1265 74.
33. Leenders KL, Wolfson L, Gibbs JM et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 1985 108 : 171 91.